Liver cancer breakthrough: surgery or pills after shrinkage?
NCT ID NCT07206511
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at patients with advanced liver cancer that cannot be removed by surgery at first. They receive a combination of treatments—chemotherapy directly into the liver, anti-angiogenic drugs, and immunotherapy—to shrink the tumor. If the tumor shrinks enough to become removable or disappears completely on scans, patients either have surgery or continue medication. The goal is to see which approach leads to better long-term outcomes, such as survival and freedom from cancer recurrence.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- combination of TACE/HAIC, anti-angiogenic agents, and immune checkpoint inhibitors
- What this could lead to
- If successful, this could help doctors decide whether surgery or continued medication is better for patients with advanced liver cancer that shrinks after initial treatment.
- What could go wrong
- This is an observational study, not a randomized trial, so results may be less definitive. The findings may not apply to all liver cancer patients, and both treatments carry risks like infection or drug side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE HEPATOCELLULAR CARCINOM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••